OssDsign Q2 FY26 operating loss widens to SEK 12.35 million; net sales rise 2.4% to SEK 37.78 million

• OssDsign posted Q2 net sales of SEK 37.78 million, up 2.4% year over year.
• Operating loss widened to SEK 12.35 million from SEK 6.94 million a year earlier.
• Net loss increased to SEK 11.41 million from SEK 8.34 million, while EPS held at SEK -0.1.
• Gross margin slipped to 92.1% from 96.8% a year earlier due to temporary mix effects.
• Preclinical study showed OssDsign Catalyst outperformed prior synthetic bone graft generations as a stand-alone trauma treatment; Adam McCollister named VP Sales.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OssDsign AB published the original content used to generate this news brief via Cision (Ref. ID: 202608180100BITN____UKPR__SV_20260817-BIT-8677-0) on August 18, 2026, and is solely responsible for the information contained therein.